NASDAQ:RDHL RedHill Biopharma - RDHL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.14 0.00 (-0.29%) (As of 03/22/2023 05:12 PM ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.14▼$0.2652-Week Range$0.13▼$3.27Volume1.54 million shsAverage Volume6.99 million shsMarket Capitalization$13.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media RedHill Biopharma MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy6.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.65) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.44 out of 5 starsMedical Sector917th out of 983 stocksPharmaceutical Preparations Industry446th out of 478 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for RedHill Biopharma. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.65% of the outstanding shares of RedHill Biopharma have been sold short.Short Interest Ratio / Days to CoverRedHill Biopharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RedHill Biopharma has recently decreased by 3.03%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRedHill Biopharma does not currently pay a dividend.Dividend GrowthRedHill Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RDHL. Previous Next 3.1 News and Social Media Coverage News SentimentRedHill Biopharma has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for RedHill Biopharma this week, compared to 1 article on an average week.Search Interest29 people have searched for RDHL on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added RedHill Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RedHill Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.81% of the stock of RedHill Biopharma is held by insiders.Percentage Held by InstitutionsOnly 5.20% of the stock of RedHill Biopharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for RedHill Biopharma are expected to grow in the coming year, from ($0.65) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RedHill Biopharma is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RedHill Biopharma is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRedHill Biopharma has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RedHill Biopharma (NASDAQ:RDHL) StockRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RDHL Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comRedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-RespondersMarch 19, 2023 | americanbankingnews.comRedHill Biopharma Stock to Reverse Split on Thursday, March 23rd (NASDAQ:RDHL)March 22, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 19, 2023 | americanbankingnews.comRedHill Biopharma Stock Set to Reverse Split on Thursday, March 23rd (NASDAQ:RDHL)March 16, 2023 | finance.yahoo.comRedHill Biopharma Announces Plan to Implement ADS Ratio ChangeMarch 8, 2023 | finance.yahoo.comRedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single InvestorFebruary 28, 2023 | finance.yahoo.comRedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures ProgramFebruary 28, 2023 | finance.yahoo.comRedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For DevelopmentMarch 22, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 16, 2023 | baystreet.caRedHill Flat on Application for Oncology DrugFebruary 16, 2023 | finance.yahoo.comRedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology SupportFebruary 16, 2023 | finance.yahoo.comRedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA PlanFebruary 15, 2023 | finance.yahoo.comRedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation SyndromeFebruary 10, 2023 | finance.yahoo.comRaleigh pharma sheds debt in exchange for top-selling drug. Now what?February 6, 2023 | finance.yahoo.comRedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik®January 26, 2023 | finance.yahoo.comRedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM DiseaseJanuary 3, 2023 | msn.comRedHill Biopharma Shares Jump After Data Publication From COVID-19 StudyJanuary 3, 2023 | markets.businessinsider.comRedHill Biopharma Reports Positive Data From Phase 2 Study Of RHB-107 In Symptomatic COVID-19January 3, 2023 | msn.comWhy RedHill Biopharma Shares Are Trading HigherJanuary 3, 2023 | finance.yahoo.comRedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19December 27, 2022 | finance.yahoo.com2022 Year in Review: Layoffs hit Triangle biotech, pharma companiesDecember 7, 2022 | finance.yahoo.comAegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)December 2, 2022 | finance.yahoo.comRedHill Biopharma Prices $8.0 Million Underwritten Public OfferingNovember 29, 2022 | finance.yahoo.comRedHill Biopharma Announces Q3/22 Results and Operational HighlightsNovember 24, 2022 | finance.yahoo.comRedHill Says Opaganib Has Potential As Nuclear Radiation Protection For Homeland Security CountermeasuresNovember 24, 2022 | finance.yahoo.comThe RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Just Cut Their Revenue Forecast By 23%November 17, 2022 | finance.yahoo.comRedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation InjurySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RDHL Company Calendar Last Earnings11/30/2021Today3/22/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees201Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,740,000.00 Net Margins-116.69% Pretax Margin-116.69% Return on Equity-9,208.02% Return on Assets-52.82% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.36 Sales & Book Value Annual Sales$85.76 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book0.78Miscellaneous Outstanding Shares96,430,000Free Float89,862,000Market Cap$12.81 million OptionableOptionable Beta2.28 Key ExecutivesMr. Dror Ben-Asher (Age 56)Co-Founder, Chairman & CEO Comp: $884.67kMr. Micha Ben-Chorin (Age 53)Chief Financial Officer Comp: $548.14kMr. Gilead Raday MPhil (Age 47)MSc, Chief Operating Officer Comp: $539.74kMr. Adi Frish (Age 52)Chief Corp. & Bus. Devel. Officer Comp: $519.65kMr. Rick D. Scruggs (Age 62)Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director Comp: $736.35kDr. Mark L. Levitt M.D.Ph.D., Chief Scientific OfficerMs. Alexandra OkmianSr. Bus. Devel. & Investor Relations Mang.Kristin ComerVP, Gen. Counsel & Chief Compliance OfficerMs. Valerie GraceffaVP of SalesMr. Rob JacksonSr. VP of Sales & MarketingMore ExecutivesKey CompetitorsGeoVax LabsNASDAQ:GOVXChemomab TherapeuticsNASDAQ:CMMBRegulus TherapeuticsNASDAQ:RGLSeFFECTOR TherapeuticsNASDAQ:EFTRBiofronteraNASDAQ:BFRIView All CompetitorsInstitutional OwnershipMillennium Management LLCSold 95,219 shares on 2/15/2023Ownership: 0.826%Morgan StanleyBought 58,128 shares on 2/15/2023Ownership: 0.695%Belvedere Trading LLCBought 9,500 shares on 2/15/2023Ownership: 0.000%Renaissance Technologies LLCBought 349,453 shares on 2/13/2023Ownership: 0.546%Group One Trading L.P.Sold 9,400 shares on 2/9/2023Ownership: 0.000%View All Institutional Transactions RDHL Stock - Frequently Asked Questions How have RDHL shares performed in 2023? RedHill Biopharma's stock was trading at $0.1403 on January 1st, 2023. Since then, RDHL stock has decreased by 5.3% and is now trading at $0.1328. View the best growth stocks for 2023 here. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) posted its earnings results on Tuesday, November, 30th. The biotechnology company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. The biotechnology company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $23.41 million. RedHill Biopharma had a negative net margin of 116.69% and a negative trailing twelve-month return on equity of 9,208.02%. During the same quarter in the prior year, the business posted ($0.50) EPS. When did RedHill Biopharma's stock split? Shares of RedHill Biopharma reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has RedHill Biopharma issued on next quarter's earnings? RedHill Biopharma updated its fourth quarter 2022 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.50 million-$15.50 million, compared to the consensus revenue estimate of $18.10 million. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). What is RedHill Biopharma's stock symbol? RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL." Who are RedHill Biopharma's major shareholders? RedHill Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.83%), Morgan Stanley (0.70%), Renaissance Technologies LLC (0.55%), Gagnon Securities LLC (0.52%), CLARET ASSET MANAGEMENT Corp (0.36%) and Belvedere Trading LLC (0.00%). How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RedHill Biopharma's stock price today? One share of RDHL stock can currently be purchased for approximately $0.13. How much money does RedHill Biopharma make? RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $12.81 million and generates $85.76 million in revenue each year. The biotechnology company earns $-97,740,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. How many employees does RedHill Biopharma have? The company employs 201 workers across the globe. How can I contact RedHill Biopharma? RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144. This page (NASDAQ:RDHL) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.